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Background: Ovarian stimulation in IVF cycle results in luteal supraphysiological steroid concentrations especially
for high response patients. The aim of this study was to evaluate the efficacy of ovarian steroid hormone
suppression in luteal phase after oocyte retrieval for preventing severe ovarian hyperstimulation syndrome (OHSS)
in high-risk patients with embryo cryopreservation.
Methods: 281 patients with high risk of OHSS were enrolled in this study among 4735 infertile women undergoing
their first IVF treatment. The subjects were allocated into treatment and control group. The treatment group (n = 161)
received letrozole (n = 43), mifepristone (n = 51), cetrotide (n = 39) and three-drug combinations (n = 28) during the
luteal phase after oocyte retrieval, respectively. The control group (n = 120) received no medicine. Fertilization rate,
good embryo rate, serum steroid concentration, clinical outcome, and incidence of severe OHSS were compared
between the two groups.
Results: On days 2, 5 and 8 after oocyte retrieval, serum estradiol levels in the letrozole and three-drug combination
therapy group were significantly lower than in the other three groups at the same time (P < 0.001, respectively). There
were no significantly difference of serum luteinizing hormone concentration on days 2, 5 and 8 and progesterone
concentration on day 8 after oocyte retreival among the five groups (P > 0.05, respectively). Compared with the control
group, the incidence of severe OHSS, the paracentesis rate, the duration of hospitalization and the days of luteal phase
in each subgroup of treatment groups was not significantly decreased (P > 0.05, respectively).
Conclusions: Our findings indicate that steroidal ovarian suppression in luteal phase after oocyte retrieval seems to be
unable to prevent severe OHSS in high-risk patients with embryo cryopreservation.
Keywords: Ovarian hyperstimulation syndrome, In vitro fertilization, Luteal phase, Mifepristone, Aromatase inhibitors,
Gonadotropin-releasing hormone antagonist, PreventionBackground
Ovarian hyperstimulation syndrome (OHSS) is a serious
iatrogenic and potentially life-threatening complication of
induced ovulation. It is caused by an exaggerated response
to gonadotropin-induced ovulation, such as the kind used
during assisted reproductive technologies. The syndrome
is characterized by cystic enlargement of the ovaries and
an increase in capillary permeability, with the consequent
acute third-space fluid sequestration and its related mor-
bidity [1, 2]. The prevention and mitigation of the* Correspondence: dryangqing@163.com
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would be a great boon to in vitro fertilization (IVF). Des-
pite many years of clinical experience, the pathophysiology
of OHSS is still obscure. Delaying embryo transfer with
embryo cryopreservation can definitely avoid pregnancy-
associated late OHSS. However, there are still no precise
methods of completely eliminating the incidence of hu-
man chorionic gonadotrophin (hCG)-induced early severe
OHSS [3].
High estradiol (E2) concentrations have been associated
with increasing likelihood of developing OHSS and there
is some evidence to suggest that coasting can significantly
reduce the incidence of severe OHSS by withdrawingis distributed under the terms of the Creative Commons Attribution 4.0
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diol concentration falls to a safer level before hCG trigger
[4–7]. Ovarian stimulation in IVF cycle also results in
supraphysiological concentrations of progesterone and es-
trogen during the luteal phase. In recent years, two studies
reported that the addition of aromatase inhibitor for high-
risk OHSS patients during the luteal phase of stimulated
donor IVF cycles significantly reduces serum estradiol
levels and impacts corpus luteum function [8, 9]. In ani-
mal studies, low doses of RU-486, an anti-progestin,
caused alterations in ovarian weight, peritoneal capillary
permeability, and the volume of ascites. These were asso-
ciated with a visible decrease in OHSS in model rats [10,
11]. This raises questions about the relationship with ovar-
ian steroid hormone levels and OHSS during the luteal
phase. Whether the suppression of ovarian steroid hor-
mone productions and promotion of regression of the cor-
pus luteum during the luteal phase after oocyte retrieval
in patients at high risk of OHSS can decrease the inci-
dence and severity of OHSS has yet to be verified.
Gonadotropin-releasing hormone antagonist (GnRH-
ant) has seen widespread use in the past two decades in
in vitro fertilization-embryo transfer (IVF-ET), where it
prevents the surge in luteinizing hormone (LH) surge and
suppression of estradiol levels in follicular phase [12]. The
use of GnRH antagonist protocol in IVF has been found
to be associated with a significantly lower incidence of
OHSS and E2 concentrations on the day of hCG adminis-
tration than on the day of treatments compared with
GnRH agonists [13, 14]. In recent years, luteal phase
GnRH-ant administration has appeared to prevent patient
hospitalization for patients with established severe early
OHSS and results in quick regression of the syndrome on
an outpatient basis [15–19]. However, the LH values fall
rapidly after oocyte retrieval in the luteal phase of the
stimulated cycles, making it unclear whether exogenous
suppression of LH levels during the luteal phase is neces-
sary? Can it really block pathogenesis of OHSS and reduce
the risk of severe OHSS? For above reasons, the specific
aim of this study was sought to investigate the relationship
between administration of steroidal ovarian suppression in
the luteal phase and OHSS.
In the present study, aromatase inhibitor, anti-
progestin, and GnRH-ant were given to patients at high
risk of OHSS in luteal phase after oocyte retrieval. The
efficacy of intervention during the luteal phase after oo-
cyte retrieval for the prevention and treatment of early-




This is a prospective, observational, cohort study per-
formed at the Reproductive Medical Center of theRenmin Hospital of Wuhan University in China from
January 2010 to December 2013. A total of 281 women
at high risk of OHSS among 4735 consecutive patients
under 38 years old planning to undergo their first IVF
treatment were included in this study. All participating
patients met at least one of the following criteria: (1)
Number of retrieved oocytes ≥ 20; (2) mean number of
follicles with a diameter greater than 14 mm ≥ 20; (3)
serum E2 concentrations reached ≥ 8 000 pg/ml; (4) on
the day of oocyte retrieval, the ovarian diameter was >
10 cm; and\presentation of obviously symptoms of
OHSS on the day of aspiration. The couples were given
counseling regarding the high risks and symptoms of
OHSS and all agreed to cancel fresh embryo transfer.
Each patient was allowed to participate in the study only
once. We strictly obeyed the Declaration of Helsinki for
Medical Research involving human subjects during the
project and written consent was obtained from all sub-
jects. The protocol was approved by the Ethical Research
Committee of Renmin Hospital of Wuhan University
(No.WHR09125).
Stimulation protocol and IVF procedure
In all the cases, a long mid-luteal GnRH agonist proto-
col was adopted for superovulation. Down-regulation
was carried out using daily GnRH agonist (triptorelin,
s.c.0.1 mg, Ferring, Pharmaceuticals, Kiel, Germany) be-
ginning on day 21 of the previous cycle, as confirmed by
a blood test. After 2–3 weeks of down-regulation, con-
firmed by a blood test and ultrasound, gonadotropin
(Gonal-F, im, 75 IU or 450 IU, Merck-Serono, Aubonne,
Switzerland) was administered intramuscularly at 112.5–
225 IU/day starting on cycle days 5–8 of stimulation. Gn
dose was adjusted according to ovarian response. All pa-
tients were monitored using transvaginal ultrasound and
serum ovarian steroid hormone concentrations during
superovulation. Final oocyte maturation was triggered
when at least three follicles ≥ 17 mm were present on
ultrasound, with administration of 6000–8000 IU
hCG injection (hCG, 1000 IU, Lizhu Pharmaceuticals,
Zhuhai, China). Transvaginal oocyte aspiration was
performed 36 h later by ultrasound-guided follicle
puncture. All embryos were cryopreserved on day 3
after IVF due to high risk of OHSS and/or severe
early-developing OHSS.
Grouping and intervention
281 consecutive high-risk patients received intra-venous
fluid administration after the day of oocyte retrieval and
were divided into a treatment group (n = 161) and
control group (n = 120). The patients in the treatment
group were informed of treatment options: letrozole
group: (n = 43) received aromatase inhibitors letrozole
tab (2.5 mg, bid, Femara; Novartis, Barcelona, Spain)
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after oocyte retrieval. Mifepristone group (n = 51): re-
ceived mifepristone tab (25 mg, bid; Zizhu Pharmaceuti-
cals, Beijin, China) per day for 3 consecutive days
beginning on the day after oocyte retrieval. GnRH-
antagonist group (n = 39): received cetrotide (0.25 mg, qd,
subcutaneous, Merck-Serono, Halle, Germany) per day for
5 consecutive days beginning on the day after oocyte re-
trieval. Three-drug combinations (Combinations) group
(n = 28): took letrozole, mifepristone and cetrotide to-
gether at the same time. The control group (n = 120): re-
ceived no special medication and was similar to the study
group with regard to basal characteristics and ART stimu-
lation parameters. In addition, 4454 patients under
38 years old planning to undergo their first IVF treatment
as the non-high risk group were included and data on
basal parameters were analyzed.
Steroid hormone assay
Blood was withdrawn from patients in all groups on days
2, 5, and 8 after oocyte retrieval. Serum E2, LH, and pro-
gesterone (P4) levels were measured using an Immulite
analyzer and commercially available kits (DPC, Los
Angeles, CA, U.S.). Analytical sensitivity were 15 pg/ml
for E2, 0.2 ng/ml for P4 and 0.1 mIU/ml for LH. Intra-
and inter-assay precisions at the concentrations of most
relevance to the current study (expressed as coefficients
of variation) were 6.1 and 6.3 % for E2, 7.8 and 10.1 %
for P4, and 5.8 and 8.2 % for LH, respectively.
Monitoring of patients
Monitoring of patients consisted of general information,
symptoms, complications during the hospitalization (ovar-
ian torsion, thromboembolic events), embryonic condi-
tion, body mass index (BMI), abdomen circumference,
ascites, and pleural effusion, urine output, days of luteal
phase, whether paracentesis had taken place, and the
amount of albumin (Alb) transfused were monitored and
recorded. Biochemical values such as hematocrit, white
blood cell count, Alb levels, blood urea nitrogen, creatin-
ine, liver enzymes, prothrombin time, and partial throm-
bin time were measured when necessary. Patients were
followed until menstruation.
The diagnostic criteria for OHSS were according to
Golan’s classification [20]. Patients with mild OHSS pre-
sented with symptoms of mild abdominal distension and
discomfort, possibly accompanied by nausea, vomiting
and diarrhea, and an ovarian diameter of ≤5 cm.
Moderate OHSS was defined as an aggravation of the
aforementioned symptoms, associated with a weight
gain of >4.5 kg, ascites identified by ultrasound exam-
ination and an ovarian diameter of 5–10 cm. Severe
OHSS was defined as marked ascites and/or hydro-
thorax, hematocrit > 45 %, white blood cell count(WBC) >15,000/mm3, dyspnea, oliguria or abnormal
liver function tests, and large ovaries (>10 cm max-
imum diameter).
Statistical analysis
Statistical analysis was performed using SPSS 12.0 statis-
tical software (Chicago, IL, U.S.) according to the
intention to treat principle. All analyses of significance
were two-sided and tested at the 5 % level. P < 0.05 was
considered statistically significant. Continuous variables
were tested if they presented normal distribution using
the F-test. The results of the multiple groups were com-
pared using the ANOVA and the comparison among
groups was performed with an LSD test. Qualitative var-
iables were assessed with the chi-squared method and
Yate’s correction. In the present study, a serum P4 level
over 60 ng/ml was taken to be 60 ng/ml exactly, because
the samples were not diluted any further.
Results
General information
In this patient cohort, the five high-risk groups were
compared for age, BMI, number of cases of polycystic
ovary syndrome (PCOS), duration of infertility, baseline
follicle-stimulating hormone (FSH), E2, duration of Gn
stimulation, and Gn dose received by the patients. No
significant differences were observed for any of the pa-
rameters (P > 0.05) (Table 1). The mean E2 concentration
on the day of HCG administration, number of follicles
with a diameter ≥14 mm, number of oocytes retrieved,
fertilization rate, cleavage rate, and quality embryo rate
were also comparable among the five high-risk
groups. But the mean E2 concentration on the day of
HCG administration, number of follicles with a diam-
eter ≥14 mm, number of oocytes retrieved, the num-
ber of usable embryos was significant decreased in
non high-risk group compare with each high-risk sub-
group (P < 0.05) (Table 2).
Serum steroid hormone levels
The serum E2, LH, and P4 concentrations were mea-
sured on days 2, 5, and 8 after oocyte retrieval. The re-
sults showed that, on days 2 and 5, the serum E2 levels
tended to increase in five high-risk groups, but on day 8,
there was an apparent gradual decrease (Fig. 1a). In five
groups, there were no significant differences in serum E2
levels on days 2, 5, and 8 after oocyte retrieval within
the cetrotide group, mifepristone group, and control
group (P > 0.05), apart from a significantly lower E2
levels in the letrozole group and three-drug group (P <
0.001). The datasets of serum E2 levels were analyzed
further on days 2, 5, and 8 in the control group. Serum
E2 levels were significantly higher in the moderate/severe
OHSS subgroup than in the mild OHSS subgroup, and
Table 1 General information of OHSS high-risk and non high-risk groups













(n = 43) (n = 51) (n = 39) (n = 28) (n = 120) (n = 4454)
Age (year) 30.6 ± 3.5 29.7 ± 4.1 29.9 ± 4.2 30.2 ± 3.8 30.1 ± 4.0 30.9 ± 3.9
BMI (kg/m2) 21.8 ± 3.3 21.5 ± 4.3 21.7 ± 3.0 21.2 ± 3.5 21.4 ± 2.9 21.3 ± 3.6
PCOS (n) 7 (16.3 %) 8 (15.7 %) 5 (12.8 %) 4 (14.3 %) 18 (15.0 %) 142 (3.2 %)
Duration of infertility (year) 4.9 ± 2.5 4.7 ± 2.8 4.6 ± 3.2 4.4 ± 3.1 4.3 ± 3.5 4.8 ± 3.6
Baseline FSH (IU/L) 5.6 ± 1.8 5.3 ± 1.7 5.9 ± 1.5 5.8 ± 1.7 6.1 ± 1.6 6.3 ± 1.5
Baseline E2 (pg/ml) 51.2 ± 19.4 49.3 ± 17.6 50.9 ± 17.8 47.4 ± 16.5 48.2 ± 18.2 46.6 ± 18.3
Duration of Gn (days) 11.1 ± 2.0 11.2 ± 1.9 10.9 ± 1.6 11.5 ± 1.8 11.3 ± 2.1 11.2 ± 2.2
Total Gn ampoules (75 IU) 24.7 ± 6.3 24.9 ± 6.8 25.3 ± 6.5 25.7 ± 6.6 25.2 ± 6.4 28.7 ± 9.8
Values are means ± SD. Values in parentheses are percentages
BMI body mass index, PCOS polycystic ovary syndrome FSH follical stimulation hormone, E2 estradiol, Gn gonadotropin
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(Fig. 2).
Serum LH levels showed that at much lower levels on
days 2, 5, and 8 (LH < 0.1 IU/L) in five groups and the
fluctuation was small (Fig. 1b). There were no signifi-
cantly difference of serum LH concentration on days 2,
5, and 8 after oocyte retrieval in five groups (P > 0.05).
The serum P4 levels were found to be >60 ng/ml on days
2 and 5, but a decrease was observed on day 8 (Fig. 1c).
There were no significant differences in serum P4 levels
on day 8 in any of the five high-risk groups (P > 0.05),
even though the serum P4 values on days 2 and 5 unable
to be compare accurately (because that the Clinical La-
boratory of Renmin Hospital did not dilute serum sam-
ples for further testing when the serum P4 concentration
was higher than 60 ng/ml). There were no significant
differences in serum LH and P4 levels in any of the
five groups, but serum E2 levels were significantly
lower in the letrozole and three-drug groups than in
the other groups.Table 2 Treatment and in vitro fertilization parameters
OHSS high-risk groups (n = 281)
Letrozole group Mifepristone group Gn
(n = 43) (n = 51) (n =
Estradiol (pg/ml)a 7871.8 ± 2527.2 8012.4 ± 2252.6 844
No. follicles with diameter > 29.2 ± 8.4 28.3 ± 7.6 30.
14 mm
No. oocytes retrieved 27.4 ± 6.6 25.1 ± 5.7 27.
Fertilization rate (%) 82.8 80.6 81.
Cleavage rate (%) 98.3 97.5 98.
Quality embryo rate (%) 62.7 60.8 63.
No. usable embryos (n) 13.2 ± 5.8 12.4 ± 4.9 13.
Values are means ± SD. Values in parentheses are percentages
*P < 0.01 compare with each high-risk subgroup
aSerum oestradiol concentration on the day of human chorionic gonadotrophin (HCClinical outcomes
All 281 patients were followed up until their next men-
ses. The clinical outcomes of patients in five groups are
shown in Table 3. The proportion of patients at high risk
for OHSS who developed moderate early OHSS was
27.9 % (12/43), 29.4 % (15/51), 33.3 % (13/39), 25.0 %
(8/28), and 27.5 % (33/120) in the letrozole group, mife-
pristone group, GnRH-ant group, three-drug group, and
control group, respectively. The incidence of severe early
OHSS in patients was 16.3 % (7/43), 19.6 % (10/51),
18.0 % (7/39), 17.9 % (5/28), and 18.3 % (22/120) in the
letrozole group, mifepristone group, GnRH-ant group,
three-drug group, and control group, respectively. The
incidence of high risk of OHSS in this IVF population
was 5.93 % (281/4735), the total incidence of severe early
OHSS was 1.18 % (55/4735) while 51 out of 55 cases
happened in risk patients.
The duration of hospitalization was 7.0 ± 2.9 days in
the letrozole group, 7.4 ± 2.5 days in the mifepristone
group, 7.1 ± 2.8 days in the GnRH-ant group, 6.8 ±OHSS non
high-risk groupRH-ant group Three-drug group Control group
39) (n = 28) (n = 120) (n = 4454)
9.3 ± 2391.8 8225.6 ± 2734.3 8437.1 ± 2885.9 2825.6 ± 1754.2*
6 ± 7.3 30.3 ± 8.1 31.1 ± 6.9 16.5 ± 6.3*
3 ± 5.9 26.8 ± 6.2 26.4 ± 6.1 12.2 ± 6.4*
1 79.7 83.2 79.5
3 97.1 97.9 98.2
1 59.7 61.9 63.6
6 ± 5.1 12.5 ± 5.6 13.7 ± 6.3 6.2 ± 2.7*
G) administration
Fig. 1 a, serum estradiol level; b, serum luteinizing hormone level;
c, serum P4 level. *P < 0.05, **P < 0.001, vs. control group
Wang et al. Journal of Ovarian Research  (2015) 8:63 Page 5 of 82.1 days in the three-drug group, and 7.3 ± 2.7 days in
the control group. The incidence of moderate or severe
OHSS and the duration of hospitalization was not
significantly lower than in the control group in any of
the treatment subgroups (P > 0.05). Paracentesis was per-
formed for drainage of abdominal fluid in severe OHSS
patients. In the letrozole group, 16.3 % (7/43) of theFig. 2 Control group a: mild OHSS patients; Control group b:
moderate/ severe OHSS patients. *P < 0.05, vs. control group Bpatients underwent paracentesis, 17.7 % (9/51) in the
mifepristone group, 17.9 % (7/39) in the GnRH-ant
group, and 14.3 % (4/28) in the three-drug group. These
values are statistically similar to the 17.5 % (21/120) in
the control group (P > 0.05).
The duration of the luteal phase (interval between
oocyte retrieval and next menstrual cycle) was 10.9 ±
2.6 days in the letrozole group, 10.5 ± 1.9 days in the
mifepristone group, 10.7 ± 2.4 days in the GnRH-ant
group, 10.4 ± 2.3 days in the three-drug group, and
11.2 ± 3.1 days in the control group. These durations
were comparable (P > 0.05). Notably, there were no
serious adverse complications during hospitalization
for OHSS observed in treatment group, but there was
one case of ovarian torsion in the control group.
Discussion
To the best of our knowledge, this is the first study to
investigate the incidence of early-onset OHSS in high-
risk patients using different types of steroidogenic sup-
pression during the luteal phase. In the present study,
the severe early OHSS occurred in the rate of 1.18 % for
all cycles, and the incidence in high-risk patients nearly
approached to 20 %, which is markedly higher than
common IVF patients. This results demonstrated that
the preferred management for the patients with potential
OHSS included early recognition of risk factors and timely
management. Ovulation induction should be highly indi-
vidualized, carefully monitored, and use the minimum
dose and duration of gonadotropin therapy necessary to
achieve the therapeutic goal. Primary preventative mea-
sures of OHSS in follicular phase included mild ovarian
stimulation, coasting, GnRH-antagonist protocol, cancel
cycle, withholding HCG or GnRH agonist trigger. If the
ovaries are overstimulated despite meticulous attention to
the above recommendations, secondary measures should
be instituted to prevent the occurrence of severe OHSS or
to minimize its severity.
Ovarian stimulation in IVF cycle results in luteal
supraphysiological steroid concentrations especially for
OHSS high-risk patients [21–24]. The current study
showed changes in serum luteal steroid concentrations
on different days in patients at high risk of OHSS. Re-
sults were consistent with those of previous studies. The
luteal E2 concentration in superovulation cycle showed
the same fluctuation as in natural cycles. However, the
absolute value of E2 was visibly higher than its natural
counterparts. Serum E2 levels of high-risk control group
with moderate/severe OHSS were significantly higher
than those of patients with mild OHSS in day 2 and day
5, and the decline in E2 on day 8 in the former subgroup
was also slower than that of the latter subgroup. This
suggests to us that serum estrogen level is, to a certain
degree, associated with severity of OHSS, and that
Table 3 OHSS outcomes of high-risk treatment and control groups
Treatment groups (n = 161) Control
groupLetrozole group Mifepristone group GnRH-ant group Three-drug group
(n = 43) (n = 51) (n = 39) (n = 28) (n = 120)
Paracentesis (n) 7 (16.3 %) 9 (17.7 %) 7 (17.9 %) 4 (14.3 %) 21 (19.2 %)
Length of hospital stay(days) 7.0 ± 2.9 7.4 ± 2.5 7.1 ± 2.8 6.8 ± 2.1 7.3 ± 2.7
Severity of OHSS
Mild (n) 24 (55.8 %) 26 (51.0 %) 19 (48.7 %) 15 (53.6 %) 65 (54.2 %)
Moderate (n) 12 (27.9 %) 15 (29.4 %) 13 (33.3 %) 8 (25.0 %) 33 (27.5 %)
Severe (n) 7 (16.3 %) 10 (19.6 %) 7 (18.0 %) 5 (17.9 %) 22 (18.3 %)
Complications (n) 0 0 0 0 1b
Luteal phase(days)a 10.9 ± 2.6 10.5 ± 1.9 10.7 ± 2.4 10.4 ± 2.3 11.2 ± 3.1
Values are means ± SD unless otherwise stated. Values in parentheses are percentages. OHSS ovarian hyperstimulation syndrome, NS not statistically significant
aLuteal phase = interval between oocyte retrieval and next menstrual cycle
bOne patient experienced ovarian torsion
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in patients who show a relatively high estrogen level on
day 2 or day 5 after oocyte retrieval. Moreover, P4 secre-
tion was here found to very exuberant, but the peak ap-
peared earlier, and the average duration of the luteal
phase is 11.3 ± 3.0 days which is shorter than nature
cycle. The results verified concept of luteolytic effect
after GnRH agonist and superovulation. Furthermore,
LH decreased to a very low level after aspiration as same
as nature cycle. According the secretion of steroid hor-
mone in luteal phase, to minimize the risk of severe
complications, secondary preventative measures are ap-
plied by different steroidogenic suppression therapy dur-
ing luteal phase for OHSS high-risk patients.
A close relationship was observed between high levels
of serum estradiol and the incidence of OHSS, as re-
ported previously by others [25–27]. After superovula-
tion, patients at high risk of OHSS have relatively high
estradiol levels not only during the follicular phase but
also during the luteal phase. Letrozole is a highly specific
non-steroidal, aromatase-selective inhibitor that can
block the conversion of androgens to estrogen [28–30].
Letrozole at doses of 1–5 mg/day can inhibit aromatase
activity by 97–99 % [31]. In the present work, results
showed that E2 levels decreased markedly on different
luteal days but there was no difference in progesterone
levels after letrozole administration. This is in consistent
with findings reported by Fatemi et al. and Garcia-
Velasco et al. [8, 9]. Unlike the Garcia-Velasco study, we
found no different in serum LH levels. Further follow-up
examination did not reveal any statistically significant
difference in the rates of severe OHSS, duration of the
luteal phase and hospitalization period between the
letrozole group and control group. The high estradiol
levels observed during the luteal phase may have been
caused by exuberant secretion from multiple corpus
luteum after superovulation in follicular phase. Exogenousaromatase inhibitor therapy during the luteal phase can-
not completely blocking OHSS in either pathogenesis or
pathophysiology.
Previous observations reported that elevated plasma
concentrations of progesterone, in addition to estradiol,
during the clinical phase of OHSS [32]. In clinical mani-
festation, the peak days of early OHSS coincide with
maximum secretion by the corpus luteum and instantly
relieves after menstruation. Severe OHSS is frequently
associated with pregnancy, which suggests that proges-
terone is involved in OHSS pathophysiology. Mifepris-
tone, a progesterone antagonist, is a synthetic steroid
hormone that binds to the progesterone receptor. It has
been predominantly and successfully used in the termin-
ation of early pregnancies [33, 34]. Ujioka et al. reported
that low doses of RU-486 (<10 mg/kg) may decrease
ovarian and peritoneal capillary permeability in hypersti-
mulated rats, probably through the anti- glucocorticoid
effect and antiprogestational activity and modulation of
vascular endothelial growth factor (VEGF) and different
cytokine effects [10, 11]. In a recent study, Yung et al.
found out that RU-486 represses LHCGR expression
and LH/hCG signaling in cultured luteinized human
mural granulosa cells [35]. In the current study, mife-
pristone was first administered during the early luteal
phase for patients at high risk of OHSS who had cryo-
preserved all embryos. The current observation shows
that steroid levels, severe OHSS rates and paracentesis
rate are not significantly different in the mifepristone
and control groups.
LH plays a crucial role in the steroidogenic activity of
the corpus luteum that takes place during the luteal
phase [36, 37]. OHSS is usually observed several days
after hCG trigger, and its severe form is frequently asso-
ciated with pregnancy or hCG supperly during the luteal
phase [20]. LH and hCG share the same α-subunit and
81 % of the amino-acid residues of the β-subunit. They
Wang et al. Journal of Ovarian Research  (2015) 8:63 Page 7 of 8also bind to the same receptor, the LH/hCG receptor. It
has been reported that luteal GnRH antagonist adminis-
tration in patients with established severe early OHSS
appears to prevent the need for patient hospitalization
and causes quick regression of the syndrome on an out-
patient basis [15–19]. Mais et al. found that administra-
tion of GnRH antagonist during the mid-luteal phase in
natural menstrual cycles could induce luteolysis by redu-
cing pulsatile gonadotrophin stimulation. This caused a
rapid decline in serum estradiol and progesterone con-
centrations and the onset of menstrual bleeding [38].
The present study, on the contrary, showed that the
luteal-phase steroid concentration is physiologically com-
parable to that of the control group and the incidence of
severe OHSS was roughly the same in the cetrotide group
and control group. These results may be explained by sev-
eral factors. First, luteal phase LH secretion is profoundly
suppressed by the pituitary via negative feedback actions
at the level of the hypothalamic-pituitary axis because of
luteal supraphysiological concentrations of progesterone
and estradiol [22–24]. Cetrotide’s anti-steroid activity is
weak on deeply suppressed LH levels. However, even
though it has been demonstrated that a few GnRH recep-
tors are expressed in the ovary, low-dose GnRH-ant exerts
only a slight an antagonistic effect there [39].
In our study, letrozole, mifepristone, and cetrotide
were co-administered and synergistic effects were ob-
served. We found that luteal steroidogenic suppression
even by three-drug combinations can’t block the on-
going process of OHSS compared with control group.
Consideration should be given to the possibility that
the overstimulated ovaries, provoked by exogenous hCG
injection, leads to the ovarian release of vasoactive-
angiogenic substances increasing the vascular permeability
and the full blown syndrome as a consequence. Anti-
steroidogenic thoerpy during the luteal phase can not fun-
damentally block the effect of hCG and pathophysiology
of OHSS.
The major limitation in this pilot cohort study was the
lack of information regarding the VEGF, interleukins and
rennin angiotensinogen system which have been impli-
cated in the pathogenesis of OHSS in the serum and as-
cites of these patients. This study is also limited by its
sample size of subgroup and non-randomized design.
No experiments were performed to compare the ef-
fects of these drugs at different dosages, the timing
or duration of treatment, or different types of anti-
steroidogenic medicine.
Conclusions
These data demonstrate that, at present, there is no dif-
ference in the rate of severe OHSS rate in patients at
high risk of OHSS, regardless of the type of luteal ste-
roidogenic suppression given. Currently, the etiology ofOHSS is not sufficiently known and therapy remains ex-
perimental. In patients at high risk of OHSS, once trig-
gered by hCG, OHSS induces a cascade of effects.
Steroidogenic suppression during the luteal phase does
not achieve a satisfactory outcome. The key to the pri-
mary prevention of OHSS during control ovarian stimu-
lation is recognition of risk factors and individualization
of the ovarian stimulation protocol. Further studies and
more patients are needed to determine how feasible it is
to completely eliminate OHSS.
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